Expired activity
Please go to the PowerPak homepage and select a course.

Clarifying the Use of Immunoglobulin Treatment in Primary Immunodeficiency

This activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Baxalta US Inc.


Elizabeth A. Cohen, PharmD
Adjunct Faculty
School of Pharmacy
University of Connecticut
Storrs, Connecticut
PGY-2 Solid Organ Transplant
Department of Pharmacy
Yale—New Haven Hospital
New Haven, Connecticut

Eric M. Tichy, PharmD, BCPS, FCCP, FAST
Manager, Clinical Pharmacy Services
Director, PGY-2 Residency Transplantation
Department of Pharmacy
Yale—New Haven Hospital
New Haven, Connecticut


Elizabeth A. Cohen, PharmD, has indicated that she has no relevant affiliations or financial relationships with a commercial interest to disclose.

Eric M. Tichy, PharmD, BCPS, FCCP, FAST, has indicated the following relevant affiliations or financial relationships: clinical investigator for Baxalta US Inc and Grifols; member of the speakers bureau for Grifols.

The following reviewer, Sachin Shah, PharmD, BCOP, FCCP, hereby states that he does not have any financial relationships or relationships to products or devices with a commercial interest related to the content of this activity.

Susanne Batesko, RN, BSN, Michele Salernitano, and Robin Carrino, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. We are committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.


acpe Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-15-044-H01-P
2.0 hour (0.20 ceu)

Type of Activity: Knowledge
Media: Internet

Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 120 minutes


July 27, 2015


July 31, 2017


This accredited activity has been designed for pharmacists.


During the period July 27, 2015 through July 31, 2017, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the posttest and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Submit Posttest at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.


This activity is designed to educate pharmacists about the types of primary immunodeficiency, the recommended treatments, and the appropriate use of immunoglobulin (IG) therapy.


Upon completion of this activity, participants should be better able to:

  1. Describe the normal immune processes;
  2. Identify common primary immunodeficiencies;
  3. Recognize the clinical presentation associated with common primary immunodeficiencies;
  4. Identify the primary immunodeficiencies for which immunoglobulin (IG) is a treatment modality;
  5. List the differences among IG products that can result from manufacturing methods;
  6. Describe the product and patient factors that should be considered when selecting an IG product;
  7. Understand the comparative efficacy and safety between intravenous and subcutaneous IG; and
  8. List the advantages and disadvantages of intravenous and subcutaneous IG.


Please ensure the computer you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft Powerpoint, Flash Player & HTML5


The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC and Baxalta US Inc. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without an evaluation of their patients' conditions and current medications, including the identification of possible contraindications regarding the dangers of use and a review of any applicable manufacturer's product information, as well as a comparison with the recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.